Search research articles
Contact Us
Filters
Showing results (81-90 of 86) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 86 results.
Breast Cancer Research and Treatment
|
January 1, 1996
Farnesyltransferase inhibitors and anti-Ras therapy
J B Gibbs, N E Kohl, K S Koblan, et al.
Biofactors (Oxford, England)
|
January 1, 1997
Farnesyl: proteintransferase inhibitors as agents to inhibit tumor growth
C A Omer, N J Anthony, C A Buser-Doepner, et al.
Nature Medicine
|
November 4, 2000
A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo
D DeFeo-Jones, V M Garsky, B K Wong, et al.
Molecular and Cellular Biology
|
January 7, 1998
A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis
R E Barrington, M A Subler, E Rands, et al.
The Lancet. Respiratory Medicine
|
September 12, 2024
Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial
Baohui Han, Trevor Feinstein, Yuankai Shi, et al.
Cancer Research
|
May 29, 2000
Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor
C A Omer, Z Chen, R E Diehl, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 86) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 86 results.
Breast Cancer Research and Treatment
|
January 1, 1996
Farnesyltransferase inhibitors and anti-Ras therapy
J B Gibbs, N E Kohl, K S Koblan, et al.
Biofactors (Oxford, England)
|
January 1, 1997
Farnesyl: proteintransferase inhibitors as agents to inhibit tumor growth
C A Omer, N J Anthony, C A Buser-Doepner, et al.
Nature Medicine
|
November 4, 2000
A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo
D DeFeo-Jones, V M Garsky, B K Wong, et al.
Molecular and Cellular Biology
|
January 7, 1998
A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis
R E Barrington, M A Subler, E Rands, et al.
The Lancet. Respiratory Medicine
|
September 12, 2024
Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial
Baohui Han, Trevor Feinstein, Yuankai Shi, et al.
Cancer Research
|
May 29, 2000
Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor
C A Omer, Z Chen, R E Diehl, et al.
Page
of 9